In vitro and in vivo assessment of inhibitory effect of stevioside on pro-inflammatory cytokines

Document Type: Short communication

Authors

1 Department of Companion Animal Clinical Science, Faculty of Veterinary Medicine, Kasetsart University, Bangkok, Thailand

2 Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

3 Department of Animal Science, Faculty of Agriculture, Kasetsart University, Bangkok, Thailand

Abstract


Objective: Stevioside is a natural non-caloric sweetener which has been reported to have anti-inflammatory activity.  The aim of  the present study was to examine in vitro and in vivo effects of  stevioside on rats  plasma levels of tumor necrosis factor- α (TNF-α),  interleukin-1β (IL-1β), TNF-α and IL-1β release from lipopolysaccharide(LPS)-stimulated rat peripheral blood mononuclear cells (PBMCs). 

Materials and Methods: Male wistar rats weighing between 170-220 g were given stevioside (0, 500 and 1000 mg/kg BW/day) for 6 weeks. Mononuclear cells were separated from peripheral blood samples.  TNF-α and IL-1β levels in plasma and the release of TNF-α and IL-1β from PBMCs were determined using rat enzyme-linked immunosorbent assay (ELISA) kits. 

Results:  Plasma levels of TNF-α and IL-1β were found to be non-detectable in control and groups treated with 500 and 1000 mg/kg of stevioside.  Regarding TNF-α release from LPS-stimulated    PBMCs, rats that were orally fed with 500 and 1000 mg/kg of stevioside were significantly different (p<0.05) from those in LPS-treated control group (186.8+18.6 and 151.4 + 15.4 vs 248.6+21.4 pg/ml).  Additionally, IL-1β levels in rats treated with 500 and 1000 mg/kg of stevioside were significantly different (p<0.05) from those in LPS-treated control group (220.0+12.1 and 158.1 + 22.6 vs 294.4+16.1 pg/ml). 

Conclusion:  Consumption of stevioside has an inhibitory effect on the release of TNF-α and IL-1β from LPS-stimulated PBMCs in rats.

Keywords

Main Subjects


Hanson JR, De Oliveira BH.  1993. Stevioside and related sweet diterpenoid glycosides. Nat Prod Rep, 10: 301-309.

Koyama E, Sakai N, Ohori Y, Kitazawa K, Izawa O, Kakekawa K, Fujino A, Ui M. 2003. Absorption and metabolism of glycosidic sweeteners of stevia mixture and their aglycone, steviol , in rats and humans.  Food Chem Toxicol, 41: 875-883.

Mosetting E.  1995. Stevioside II. The structure of the aglycone.  J Org Chem, 20: 884-899.

Koyama E, Kitazawa K, Ohori Y, Izawa O, Kakegawa K, Fujino A, Ui  M.  2003. In vitro metabolism of the glycosidic sweeteners, stevia in human intestinal microflora. Food Chem Toxicol, 41 : 359-374.

Geuns JM, Buyse J,  Vankeirsbilck A, Temme EH.  2007. Metabolism of stevioside by healthy subjects.  Exp Biol Med, 232: 164-173.

Chatsudthipong V,  Muanprasat C.  2009. Stevioside  and  related compounds: therapeutic  benefit  beyond sweetness.  Pharmacol Ther, 121: 41-54.

Jeppesen PB, Kyrskog SE, Agger A, Gregersen XJ, Hermansen K.  2006. Can stevioside in combination with a soy-based dietary supplement be a new useful treatment of type 2 diabetes? An in vivo Studies in the diabetic goto-Kakizaki Rat. Rev Diabet Stud, 3: 189-199.

Lee CN, Wong K, Liu J, Chen Y, Chen J, Chan P.  2001. Inhibitory effect of stevioside on calcium influx to produce antihypertension.  Planta Med, 67: 796-799.

Boonkaewwan C, Toskulkao  C,  Vongsakul M.  2006. Anti-inflammatory and Immunomodulatory Activities of Stevioside and Its Metabolite Steviol on THP-1  Cells.  J Agric Food Chem, 54: 785-789.

Boonkaewwan C, Ao M, Toskulkao  C,  Rao MC.  2008. Specific immunomodulatory and  secretory activities of stevioside and steviol in intestinal cells.  J Agric Food Chem, 56: 3777-3784.

Boonkaewwan C,  Burodom  A.   2013. Anti-inflammatory and immunomodulatory activities of stevioside and steviol on colonic epithelial cells. J Sci Food Agric  ,  93:  3820–3825.

Pariwat P, Homvisasevongsa S,  Muanprasa  C,  Chatsudthipong V.   2008. A natural plant-derived . dihydroisosteviol prevents cholera toxin-induced intestinal fluid secretion. J Pharmcol Exp Ther, 324: 798-805.

Freeman BD, Natanson C.  2000. Anti-inflammatory therapies in sepsis and septic shock.  Expert  Opin  Inv  Drugs, 9: 1651-1663.

Adduci J, Buddhasukh D, Ternai B.  1987. Improved isolation and purification of stevioside.  J  Sci  Soc Thailand, 12: 179-183.

Boyum A.  1968. Isolation of mononuclear cells and granulocytes from human blood.  Scand J Clin Lan Invert, 21: 77-89.

Morikawa K, Watabe H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother. 1996; 40:1366-70.

Robak T, Gladalska A, Stepien H.  1998. The tumour necrosis factor family of receptors/ligands in the serum of patients with rheumatoid arthritis.  Eur Cytokine Netw, 9:145-154.

Rabinovitch A,  Suarez-Pinzon WL.  2003. Role of cytokines in the pathogenesis of autoimmune diabetes mellitus.  Rev Endocr Metab Disord, 4:291-299.

JECTA. 2008. Steviol glycosides. In: Compendium of Food Additive Specifications FAO/WHO Expert Committee on Food Additives (JECFA), 69th Meeting, 17-26 June FAO/JECFA monographs  no 5) Rome: Food and Agriculture Organization of the United  Nations/World Health Oraganization; 75-78.